Expressing a protein from the genes of Batroxobin in yeast with the gene recombinant technology, for overcoming the limitation of human origin thrombin
Cutting Fibrinogen α Chain at bleeding area into DesAA Fibrin
Easy to supply (A protein expressed in Yeast)
Non animal origin, No risk of virus infection and practice of animal welfare
Possible the distribution and storage at the room temperature
Enable the product standardization through the simple production process
Available for injection because of not affecting coagulation factors and platelets
Not affected by anticoagulants such as heparin
Highly marketable, able to get approvals everywhere in the world
rTLH is in synergy with Carboxymethyl chitosan to high haemostasis effect by maximizing enzyme activity and strengthening blood coagulation.
It induces the exudate absorption and coagulation of
blood platelet & red blood cell. The created blood clot protects the
wound by the role of mechanical barrier.
It cuts Fibrinogen’s α chain. (Fibrinogen to DesAA Fibrin)
DesAA Fibrin combines with platelets aggregation, forming the blood clot.
That is, rTLH helps the activated thrombin at bleeding area, promoting hemostasis.
